Nektar Therapeutics

J.P. Morgan is out with its report today on Nektar Therapeutics (NASDAQ: NKTR), reiterating Overweight. In a note to clients, J.P. Morgan writes, "We have an OW rating on NKTR as we see it as an attractive long term biotech holding. Our view is based the potential of the company to leverage its...

According to J.P. Morgan, Nektar Therapeutics (NASDAQ: NKTR) maintains its Overweight rating. J.P. Morgan said that it recently surveyed 50 oncologists to assess current sentiment for NKTR-102 as a potential therapy for metastatic breast cancer (mBC). “At this relatively early juncture, physicians...

Deutsche Bank is maintaining its Buy rating and its $14 price target on Nektar Therapeutics (NASDAQ: NKTR) based upon the company's in-line Q1 results. According to Deutsche Bank, “With a steadily growing royalty stream from 9 products, 6 programs in late-stage development (1 proprietary, 5...

Nektar Therapeutics (NASDAQ: NKTR) reported 1Q11 revenue of $11.3 million and EPS of $(0.33), “both of which are below consensus of $17.2 and $(0.27), but neither truly matter at this point in Nektar's development,” Brean Murray reports. Nektar Therapeutics closed Wednesday at $9.96.

J.P. Morgan is out with its report today on Nektar Therapeutics (NASDAQ: NKTR), lowering its price target from $17 to $15. In a note to clients, J.P. Morgan writes, "Despite the disappointing performance of NKTR's shares since the surprising decision to go it along with NKTR-102 in Dec, we still...

Hapoalim is out with its report on Nektar Therapeutics (NASDAQ: NKTR), lowering its price target from $19 to $17. In a note sent to clients, Hapoalim writes, "Nektar is moving slowly on the planning of its Phase 3 program for NKTR-102 in breast and ovarian cancer, implying 2012 will now be the year...

JP Morgan has lowered the price target on Nektar Therapeutics (NASDAQ: NKTR) from $17 to $15 and maintains its Overweight rating.

Deutsche Bank released its report on Nektar Therapeutics (NASDAQ: NKTR) following NKTR's annoucement of positive Ph 2 results for NKTR-102, in metastatic breast cancer at the CTRC-AACR San Antonio Breast Cancer Symposium. In a note to clients, Deutsche Bank writes, "Based on a combination of the...

Hapoalim Securities has published a research report on Nektar Therapeutics (NASDAQ: NKTR) after the company announced positive news from the full Phase 2 trial of NKTR-102. In the report, Hapoalim writes "Nektar announced positive results from a Phase 2 clinical study evaluating single-agent NKTR-...

J.P. Morgan reports that over the weekend, Nektar Therapeutics (NASDAQ: NKTR) presented promising Ph2 data for NKTR-102 in second line metastatic breast cancer (mBC) at the San Antonio Breast Cancer Symposium (SABCS) wherein the objective response rate improved since this summer's topline update (...